vs
Red Violet, Inc.（RDVT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Red Violet, Inc.的1.3倍（$30.3M vs $23.4M），Red Violet, Inc.净利率更高（12.0% vs -221.3%，领先233.4%），REGENXBIO Inc.同比增速更快（43.0% vs 19.6%），Red Violet, Inc.自由现金流更多（$6.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.6%）
Red Violet, Inc.是一家专注于高级数据分析、风险缓释与身份验证解决方案的科技企业，服务覆盖执法、金融服务、保险、企业合规等多个领域，通过整合公开及专有数据集为客户提供可落地的决策参考洞察。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
RDVT vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.4M
营收增速更快
RGNX
高出23.4%
19.6%
净利率更高
RDVT
高出233.4%
-221.3%
自由现金流更多
RDVT
多$59.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.4M | $30.3M |
| 净利润 | $2.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 6.8% | -190.0% |
| 净利率 | 12.0% | -221.3% |
| 营收同比 | 19.6% | 43.0% |
| 净利润同比 | 226.2% | -31.2% |
| 每股收益（稀释后） | $0.20 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDVTRGNX
| Q4 25 | $23.4M | $30.3M | ||
| Q3 25 | $23.1M | $29.7M | ||
| Q2 25 | $21.8M | $21.4M | ||
| Q1 25 | $22.0M | $89.0M | ||
| Q4 24 | $19.6M | $21.2M | ||
| Q3 24 | $19.1M | $24.2M | ||
| Q2 24 | $19.1M | $22.3M | ||
| Q1 24 | $17.5M | $15.6M |
净利润RDVTRGNX
| Q4 25 | $2.8M | $-67.1M | ||
| Q3 25 | $4.2M | $-61.9M | ||
| Q2 25 | $2.7M | $-70.9M | ||
| Q1 25 | $3.4M | $6.1M | ||
| Q4 24 | $863.0K | $-51.2M | ||
| Q3 24 | $1.7M | $-59.6M | ||
| Q2 24 | $2.6M | $-53.0M | ||
| Q1 24 | $1.8M | $-63.3M |
毛利率RDVTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率RDVTRGNX
| Q4 25 | 6.8% | -190.0% | ||
| Q3 25 | 19.8% | -176.3% | ||
| Q2 25 | 12.6% | -296.3% | ||
| Q1 25 | 19.1% | 13.6% | ||
| Q4 24 | 1.9% | -242.1% | ||
| Q3 24 | 13.1% | -256.6% | ||
| Q2 24 | 16.1% | -251.3% | ||
| Q1 24 | 11.3% | -408.8% |
净利率RDVTRGNX
| Q4 25 | 12.0% | -221.3% | ||
| Q3 25 | 18.3% | -208.3% | ||
| Q2 25 | 12.3% | -331.8% | ||
| Q1 25 | 15.6% | 6.8% | ||
| Q4 24 | 4.4% | -241.3% | ||
| Q3 24 | 9.0% | -246.3% | ||
| Q2 24 | 13.8% | -237.7% | ||
| Q1 24 | 10.2% | -405.4% |
每股收益（稀释后）RDVTRGNX
| Q4 25 | $0.20 | $-1.30 | ||
| Q3 25 | $0.29 | $-1.20 | ||
| Q2 25 | $0.18 | $-1.38 | ||
| Q1 25 | $0.24 | $0.12 | ||
| Q4 24 | $0.06 | $-0.99 | ||
| Q3 24 | $0.12 | $-1.17 | ||
| Q2 24 | $0.19 | $-1.05 | ||
| Q1 24 | $0.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $100.9M | $102.7M |
| 总资产 | $112.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RDVTRGNX
| Q4 25 | $43.6M | $230.1M | ||
| Q3 25 | $45.4M | $274.2M | ||
| Q2 25 | $38.8M | $323.3M | ||
| Q1 25 | $34.6M | $267.9M | ||
| Q4 24 | $36.5M | $234.7M | ||
| Q3 24 | $35.7M | $255.5M | ||
| Q2 24 | $30.9M | $290.4M | ||
| Q1 24 | $32.1M | $338.7M |
股东权益RDVTRGNX
| Q4 25 | $100.9M | $102.7M | ||
| Q3 25 | $101.7M | $161.5M | ||
| Q2 25 | $96.2M | $213.7M | ||
| Q1 25 | $91.8M | $274.2M | ||
| Q4 24 | $86.6M | $259.7M | ||
| Q3 24 | $91.7M | $301.4M | ||
| Q2 24 | $88.0M | $348.3M | ||
| Q1 24 | $83.8M | $390.7M |
总资产RDVTRGNX
| Q4 25 | $112.0M | $453.0M | ||
| Q3 25 | $112.1M | $525.2M | ||
| Q2 25 | $104.8M | $581.0M | ||
| Q1 25 | $99.1M | $490.9M | ||
| Q4 24 | $98.5M | $466.0M | ||
| Q3 24 | $98.0M | $519.1M | ||
| Q2 24 | $93.5M | $569.4M | ||
| Q1 24 | $94.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 28.1% | -174.0% |
| 资本支出强度资本支出/营收 | 0.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.38× | — |
| 过去12个月自由现金流最近4个季度 | $28.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流RDVTRGNX
| Q4 25 | $6.7M | $-52.3M | ||
| Q3 25 | $10.2M | $-56.0M | ||
| Q2 25 | $7.5M | $-49.3M | ||
| Q1 25 | $5.0M | $33.6M | ||
| Q4 24 | $6.7M | $-31.6M | ||
| Q3 24 | $7.2M | $-40.5M | ||
| Q2 24 | $5.7M | $-45.5M | ||
| Q1 24 | $4.3M | $-55.5M |
自由现金流RDVTRGNX
| Q4 25 | $6.6M | $-52.8M | ||
| Q3 25 | $10.0M | $-56.5M | ||
| Q2 25 | $7.3M | $-49.7M | ||
| Q1 25 | $5.0M | $32.6M | ||
| Q4 24 | $6.7M | $-32.7M | ||
| Q3 24 | $7.2M | $-40.9M | ||
| Q2 24 | $5.7M | $-46.0M | ||
| Q1 24 | $4.2M | $-56.0M |
自由现金流率RDVTRGNX
| Q4 25 | 28.1% | -174.0% | ||
| Q3 25 | 43.3% | -189.9% | ||
| Q2 25 | 33.5% | -232.8% | ||
| Q1 25 | 22.5% | 36.6% | ||
| Q4 24 | 34.1% | -154.2% | ||
| Q3 24 | 37.8% | -168.9% | ||
| Q2 24 | 29.7% | -206.2% | ||
| Q1 24 | 24.2% | -358.5% |
资本支出强度RDVTRGNX
| Q4 25 | 0.5% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率RDVTRGNX
| Q4 25 | 2.38× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.79× | — | ||
| Q1 25 | 1.45× | 5.53× | ||
| Q4 24 | 7.75× | — | ||
| Q3 24 | 4.22× | — | ||
| Q2 24 | 2.17× | — | ||
| Q1 24 | 2.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDVT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
